Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Maintains Neutral on GitLab, Lowers Price Target to $69

Goldman Sachs maintains GitLab (NASDAQ:GTLB) with a Neutral and lowers the price target from $86 to $69.

byBenzinga Newsdesk

April 14, 2022

1 minute read

Goldman Sachs maintains GitLab (NASDAQ:GTLB) with a Neutral and lowers the price target from $86 to $69.

Atreca Q2 EPS $(0.72), Same YoY

By Benzinga Newsdesk

Today, 10:34 PM

Atreca (NASDAQ:BCEL) reported quarterly losses of $(0.72) per share. This is unchanged from the same period last year.

BCEL

Earlier Announced Termination Of Dipraglurant Phase 2b/3 Study In Patients With Dyskinesia Associated With Parkinson’s Disease due To Slow Recruitment Rate; Co. Also Announced Suspension Of Guidance Amid Termination

By Bill Haddad

Today, 10:34 PM

COVID-19 related challenges negatively impacted patient recruitment Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 17, 2022- Addex Therapeutics

ADXN

Chimerix Shares Spike Higher; FDA Approves Co’s Tembexa To Treat Smallpox

By Benzinga Newsdesk

Today, 10:34 PM

https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-treat-smallpox

CMRX

Analyst Ratings

What 9 Analyst Ratings Have To Say About Shoals Technologies Gr

By Benzinga Insights

Today, 10:34 PM

Over the past 3 months, 9 analysts have published their opinion on Shoals Technologies Gr (NASDAQ:SHLS) stock. These…

SHLS

Goldman Sachs Maintains Neutral on GitLab, Lowers Price Target to $69

Related Posts

Atreca Q2 EPS $(0.72), Same YoY

Earlier Announced Termination Of Dipraglurant Phase 2b/3 Study In Patients With Dyskinesia Associated With Parkinson’s Disease due To Slow Recruitment Rate; Co. Also Announced Suspension Of Guidance Amid Termination

Chimerix Shares Spike Higher; FDA Approves Co’s Tembexa To Treat Smallpox

What 9 Analyst Ratings Have To Say About Shoals Technologies Gr